Low-dose AtropIne for Myopia control in children (AIM-study)

• Applicant: Professor Dr. Wolf A. Lagrèze
• Subject Area: Ophthalmology
• Term: since 2019
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 416728216

Myopia (short-sightedness) is increasing worldwide, however mainly in Asia. If the degree of myopia exceeds a certain threshold, known as high myopia, the risk of diseases in the posterior segment of the eye increases significantly in later life. It is therefore a therapeutic goal to minimise the progression of myopia, namely when it develops and its progression is most pronounced, i.e. between the ages of around 7 and 14. The topical administration of atropine has been firmly established since around 10 years. Evidence in favour of this therapy comes mainly from Asian studies. New studies outside Asia have also shown significant, but weaker effects. The safety of this therapy can be regarded as highly favourable. The DFG is currently funding the German AIM-trial, which has been recruiting since autumn 2021 and will reach its recruitment target of 300 children in autumn 2024. We are submitting an extension application for this study in order to successfully complete this clinically very important project.

• DFG Programme: Clinical Trials
• Co-Investigator: Navid Farassat, Ph.D.